The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.
Wohl, D A
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir. [electronic resource] - HIV medicine Feb 2016 - 106-17 p. digital
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1468-1293
10.1111/hiv.12281 doi
Adult
Anti-HIV Agents--therapeutic use
Antiretroviral Therapy, Highly Active
Atazanavir Sulfate--therapeutic use
Biomarkers--blood
Bone Density--drug effects
CD4 Lymphocyte Count
Dideoxynucleosides--therapeutic use
Drug Combinations
Drug Substitution--methods
Female
HIV Infections--blood
Humans
Kidney--drug effects
Lamivudine--therapeutic use
Lipids--blood
Male
Middle Aged
RNA, Viral--blood
Ritonavir--adverse effects
Treatment Outcome
Viral Load
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir. [electronic resource] - HIV medicine Feb 2016 - 106-17 p. digital
Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
1468-1293
10.1111/hiv.12281 doi
Adult
Anti-HIV Agents--therapeutic use
Antiretroviral Therapy, Highly Active
Atazanavir Sulfate--therapeutic use
Biomarkers--blood
Bone Density--drug effects
CD4 Lymphocyte Count
Dideoxynucleosides--therapeutic use
Drug Combinations
Drug Substitution--methods
Female
HIV Infections--blood
Humans
Kidney--drug effects
Lamivudine--therapeutic use
Lipids--blood
Male
Middle Aged
RNA, Viral--blood
Ritonavir--adverse effects
Treatment Outcome
Viral Load